• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组人α-2C干扰素治疗原发性血小板增多症的疗效

Therapeutic effect of human recombinant interferon-alpha-2C in essential thrombocythaemia.

作者信息

Velu T, Delwiche F, Gangji D, Monsieur R, Flament J, Stryckmans P, Wybran J, Bellens R

出版信息

Oncology. 1985;42 Suppl 1:10-4. doi: 10.1159/000226078.

DOI:10.1159/000226078
PMID:4080296
Abstract

Human recombinant interferon-alpha 2C was given to 4 patients with essential thrombocythaemia. Three patients achieved a complete remission on day 19 +/- 1 and the 4th achieved a partial remission. After 4 weeks of induction therapy, a maintenance therapy of twice weekly intramuscular injections of 5 X 10(6) or 10 X 10(6) IU was instituted but did not maintain the remission.

摘要

将重组人干扰素α-2C给予4例原发性血小板增多症患者。3例患者在第19±1天实现完全缓解,第4例实现部分缓解。诱导治疗4周后,开始每周两次肌肉注射5×10⁶或10×10⁶国际单位的维持治疗,但未能维持缓解状态。

相似文献

1
Therapeutic effect of human recombinant interferon-alpha-2C in essential thrombocythaemia.重组人α-2C干扰素治疗原发性血小板增多症的疗效
Oncology. 1985;42 Suppl 1:10-4. doi: 10.1159/000226078.
2
Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.重组干扰素α-2C治疗:骨髓增殖性疾病中的多发性骨髓瘤和血小板增多症
Oncology. 1985;42 Suppl 1:19-25. doi: 10.1159/000226080.
3
Treatment of essential thrombocythaemia by alpha 2a interferon.α2a干扰素治疗原发性血小板增多症
Lancet. 1988 Oct 22;2(8617):960-1. doi: 10.1016/s0140-6736(88)92625-6.
4
Recombinant interferon-alpha, but not interferon-gamma is effective therapy for essential thrombocythemia.
Blut. 1990 Jan;60(1):37-40. doi: 10.1007/BF01720201.
5
Alpha-interferon therapy for essential thrombocythaemia.
Lancet. 1988 Jul 9;2(8602):70-2. doi: 10.1016/s0140-6736(88)90005-0.
6
Recombinant alpha-2a interferon (alpha-IFN) in the treatment of essential thrombocythaemia. Preliminary report.重组α-2a干扰素(α-干扰素)治疗原发性血小板增多症。初步报告。
Haematologica. 1987 May-Jun;72(3):277-9.
7
Treatment of essential thrombocythaemia by alpha-interferon.α干扰素治疗原发性血小板增多症
Lancet. 1988 Sep 10;2(8611):628. doi: 10.1016/s0140-6736(88)90664-2.
8
[Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
Acta Med Austriaca. 1985;12(5):123-7.
9
Interferon in essential thrombocythaemia.
Br J Haematol. 1991 Oct;79 Suppl 1:42-7. doi: 10.1111/j.1365-2141.1991.tb08118.x.
10
Treatment of essential thrombocythaemia with interferon alpha-2b.α-2b干扰素治疗原发性血小板增多症
Lancet. 1989 Jan 14;1(8629):96. doi: 10.1016/s0140-6736(89)91446-3.

引用本文的文献

1
Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.骨髓增殖性肿瘤中的下一代测序。过去的经验教训以及用作预后和治疗反应预测指标的前景。
Cancers (Basel). 2020 Aug 6;12(8):2194. doi: 10.3390/cancers12082194.
2
Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.干扰素-α可纠正骨髓增殖性疾病患者的血小板增多症。
Cancer Immunol Immunother. 1987;25(3):266-73. doi: 10.1007/BF00199157.
3
The role of interferons in the treatment of malignant neoplasms.
干扰素在恶性肿瘤治疗中的作用。
Yale J Biol Med. 1989 May-Jun;62(3):271-90.
4
Recombinant interferon-alpha, but not interferon-gamma is effective therapy for essential thrombocythemia.
Blut. 1990 Jan;60(1):37-40. doi: 10.1007/BF01720201.
5
Interferon alpha-2b in the long-term treatment of essential thrombocythemia.干扰素α-2b用于原发性血小板增多症的长期治疗。
Ann Hematol. 1991 Oct;63(4):206-9. doi: 10.1007/BF01703444.